Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 16/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3059786 | 0.83 | SLC6A9 (0.63) | SLC6A9HPGDKMT2AMEN1GPR27 | |
| SCHEMBL3059626 | 0.81 | SLC6A9 (0.60) | SLC6A9HPGDKMT2AMEN1GPR27 | |
| SCHEMBL3055700 | 0.80 | SLC6A9 (0.59) | SLC6A9HPGDKMT2AMEN1GPR27 | |
| SCHEMBL3053102 | 0.78 | SLC6A9 (0.48) | SLC6A9 | |
| SCHEMBL3042562 | 0.74 | SLC6A9 (0.68) | SLC6A9 | |
| SCHEMBL8244583 | 0.74 | SLC6A9 (0.68) | SLC6A9 | |
| SCHEMBL7795359 | 0.73 | SLC6A9 (1.00) | SLC6A9 | |
| SCHEMBL2850636 | 0.72 | SLC6A9 (1.00) | SLC6A9 | |
| SCHEMBL2854460 | 0.72 | SLC6A9 (0.60) | SLC6A9HPGDKMT2AMEN1 | |
| SCHEMBL2850232 | 0.69 | SLC6A9 (0.64) | SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222317-A1 | Azetidine Derivatives as GlyT1 Inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222317-A1 | Azetidine Derivatives as GlyT1 Inhibitors | GRIA1, GLRA1, GRIN1 | SLC6A9 18/4885HPGD 2932/4885KMT2A 1755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.